, , , , , , , , ,

CVS Health will begin manufacturing cheaper ‘biosimilar’ drugs

CVS Health is launching a new subsidiary unit, Cordavis, that will collaborate with drug manufacturers to produce biosimilar products, or medications that are near identical to an already approved and existing drug. This unit will commercialize and co-produce FDA-approved biosimilar products to U.S. markets, which will likely have a trickle-down effect on the way consumers buy drugs by increasing competition and driving down prices.

This subsidiary will not reinvent the wheel with new drugs. All the biosimilar products produced will be highly similar to an already approved biologic medicine but will still undergo testing and approvals to ensure they are highly comparable in terms of safety, efficacy and quality. If generic drugs are the Kirkland brand of medication — an identical product made cheaper through the expiration of a patent — biosimilars are more like Amazon Basics: less expensive, legally distinct but functionally the same as what they imitate. CVS claims that Cordavis will "help ensure consistent long-term supply of affordable biosimilars" when it officially debuts at the beginning of 2024.

The first confirmed offering from Cordavis in the near future is Hyrimo, a biosimilar of the drug Humira. Humira is an injectable drug that is used to treat a range of diseases, including Crohn's and rheumatoid arthritis in adults. The drug is a popular prescription that generated its maker AbbVie net revenues of $3.5 billion in global sales in the second quarter of 2023. It has a list price of nearly $7,000 a month, making it a prime drug worth diluting in the competitive pharmaceutical landscape. Cordavis says its biosimilar for Humira will list under a new private label and will be 80 percent cheaper than the current list price of the drug. This early offering gives just a snapshot of the kind of influence Cordavis can have on disruption in the drug manufacturing space.

This article originally appeared on Engadget at https://www.engadget.com/cvs-health-will-begin-manufacturing-cheaper-biosimilar-drugs-153019696.html?src=rss

https://www.engadget.com/cvs-health-will-begin-manufacturing-cheaper-biosimilar-drugs-153019696.html?src=rss


November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  

About Us

Welcome to encircle News! We are a cutting-edge technology news company that is dedicated to bringing you the latest and greatest in everything tech. From automobiles to drones, software to hardware, we’ve got you covered.

At encircle News, we believe that technology is more than just a tool, it’s a way of life. And we’re here to help you stay on top of all the latest trends and developments in this ever-evolving field. We know that technology is constantly changing, and that can be overwhelming, but we’re here to make it easy for you to keep up.

We’re a team of tech enthusiasts who are passionate about everything tech and love to share our knowledge with others. We believe that technology should be accessible to everyone, and we’re here to make sure it is. Our mission is to provide you with fun, engaging, and informative content that helps you to understand and embrace the latest technologies.

From the newest cars on the road to the latest drones taking to the skies, we’ve got you covered. We also dive deep into the world of software and hardware, bringing you the latest updates on everything from operating systems to processors.

So whether you’re a tech enthusiast, a business professional, or just someone who wants to stay up-to-date on the latest advancements in technology, encircle News is the place for you. Join us on this exciting journey and be a part of shaping the future.

Podcasts

TWiT 1007: All the Hotdogs in the World – China's 'Salt Typhoon' Hack, Google on the Chopping Block, Recall AI This Week in Tech (Audio)

In this episode of This Week in Tech, the panel tackles the "biggest hack in US history," the future of AI, and the role of government in tech. From the Chinese hack's implications to Microsoft's AI-powered Recall, the Supreme Court's tech-related cases, and the push for social media age verification, Leo Laporte, Patrick Beja, Wesley Faulkner, and Alex Wilhelm provide insightful analysis and lively discussion on the most pressing issues facing the industry today. China's "Salt Typhoon" hack, dubbed the "worst hack in our nation's history," which compromised US telecommunications infrastructure and allowed surveillance of high-profile individuals The panel debates the challenges of securing outdated infrastructure and the role of government in regulating tech companies DOJ's push for Google to sell off Chrome to break its search monopoly, and the potential implications for competition and innovation Alex Wilhelm's article "If you like startups, you should love anti-trust" and the importance of fostering competition in the tech industry Microsoft's Windows 365 Link, a $349 mini PC that streams Windows from the cloud, and the potential for thin client computing Microsoft's Recall AI feature, which records and indexes users' screen activity, raising security concerns but offering potential benefits for users The Supreme Court's involvement in cases related to Facebook's Cambridge Analytica data breach and the fate of America's low-income broadband fund The panel also discusses their personal experiences with parenting in the digital age and the challenges of balancing screen time, privacy, and education for children Meta's push for Apple and Google to verify users' ages on social media platforms, and the challenges of implementing effective age verification while protecting user privacy Amazon's talks with Instacart, Uber, Ticketmaster, and others to enhance its AI-powered Alexa assistant Spirit Airlines filing for bankruptcy amidst financial losses and mounting debt payments Alex laments the addition of ads to Amazon Prime Video and the panel debates the tradeoffs of bundled subscription services Host: Leo Laporte Guests: Patrick Beja, Wesley Faulkner, and Alex Wilhelm Download or subscribe to This Week in Tech at https://twit.tv/shows/this-week-in-tech Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit Sponsors: Melissa.com/twit shopify.com/twit veeam.com lookout.com bitwarden.com/twit
  1. TWiT 1007: All the Hotdogs in the World – China's 'Salt Typhoon' Hack, Google on the Chopping Block, Recall AI
  2. TWiT 1006: Underwater Alien Civilizations – Bluesky Growth, Tyson Vs. Paul, AI Granny
  3. TWiT 1005: $125,000 in Baguettes – iPod Turns 23, The $1.1M AI Painting, Roblox
  4. TWiT 1004: Embrace Uncertainty – Political Texts, Daylight Saving Time, Digital Ad Market
  5. TWiT 1003: CrabStrike – Delta Sues Crowdstrike, Hospital AI, Surge Pricing